Goldman Sachs Group Inc Neurocrine Biosciences Inc Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 737,437 shares of NBIX stock, worth $90.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
737,437
Previous 737,437
-0.0%
Holding current value
$90.7 Million
Previous $81.6 Million
-0.0%
% of portfolio
0.01%
Previous 0.01%
Shares
21 transactions
Others Institutions Holding NBIX
# of Institutions
650Shares Held
97.2MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.75 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.22 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$681 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$598 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$329 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...